ProfileGDS5678 / 1416591_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 84% 87% 85% 87% 90% 90% 90% 90% 88% 88% 87% 87% 87% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.7592188
GSM967853U87-EV human glioblastoma xenograft - Control 26.2996984
GSM967854U87-EV human glioblastoma xenograft - Control 36.7304287
GSM967855U87-EV human glioblastoma xenograft - Control 46.6228385
GSM967856U87-EV human glioblastoma xenograft - Control 56.8120187
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.9519790
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.0964390
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.096390
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.210490
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.8421988
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.7883688
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.8073687
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6209487
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.6140887